Liver Transplantation, Major Adverse Cardiovascular Events
Conditions
Keywords
statin, liver transplantation, major adverse cardiovascular events
Brief summary
The goal of this multicenter observational study is to determine whether preoperative statin use reduces major adverse cardiovascular events or other complications after liver transplantation. The main question it aims to answer is: Does preoperative statin use reduce major adverse cardiovascular events or other complications after liver transplantation? The records of participants who already took statins before liver transplantation will be reviewed.
Detailed description
Cardiovascular complications have emerged as a leading cause of early postoperative death following liver transplantation (LT), accounting for over 40% of early deaths. As a result, preventing postoperative cardiac complications has become a critical concern in the management of LT recipients. Statin therapy has been suggested to improve perioperative and long-term outcomes in various surgical populations, primarily through LDL cholesterol reduction as well as pleiotropic effects, such as enhanced endothelial function and anti-inflammatory actions. However, evidence specifically examining the impact of preoperative statin therapy on cardiovascular outcomes after LT remains limited, highlighting the need for further research in this population. This study aimed to address the current knowledge gap by investigating the association between preoperative statin use and the incidence of major adverse cardiovascular events within 30 days after liver transplantation in liver transplant recipients. Secondary outcomes included overall mortality, graft failure, early allograft dysfunction, acute kidney injury, and length of stay in the intensive care unit.
Interventions
DRUGPreoperative Statin Use
Administration of any statin medication prior to liver transplantation. Statin therapy was previously prescribed by the treating physician before the transplant procedure, not assigned by the study protocol.
Sponsors
Asan Medical Center
Samsung Medical Center
Inje University Haeundae Paik Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Adult patients aged ≥18 years who underwent liver transplantation
Exclusion criteria
* Patients who underwent liver re-transplantation * Patients with preoperative acute-on-chronic liver failure (ACLF) * Patients with preoperative fulminant hepatic failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30-day Major Adverse Cardiovascular Events | 30 days after liver transplantation | The composite of cardiovascular death, heart failure, myocardial infarction, atrial fibrillation, ventricular arrhythmia, ischemic electrocardiogram changes (ST-segment depression or elevation) with chest tightness, pulmonary embolism, and stroke |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute Kidney Injury | Within 7 days after liver transplantation | Occurrence of acute kidney injury within 7 days post-transplantation, diagnosed according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria |
| Early Allograft Dysfunction | Within 7 days after liver transplantation | Defined as serum bilirubin \>10 mg/dL or international normalized ratio (INR) \>1.6 on postoperative day (POD) 7, or alanine/aspartate aminotransferases \>2000 IU/L within 7 days after transplantation |
| Intensive Care Unit Length of Stay | From the date of liver transplantation until intensive care unit discharge, up to 600 days | Total duration (days) of intensive care unit stay after liver transplantation |
| Overall Mortality | From the date of liver transplantation to Mar 22, 2026 | Death from any cause after liver transplantation |
| Overall Graft Failure | From the date of liver transplantation to Mar 22, 2026 | Recipient death or retransplantation for any cause |
Countries
South Korea
Outcome results
None listed